Liyun Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liyun Feng has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- An Chen
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China. (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.)
4 shared publications - Jianyun Yan
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Guangzhou, 510280, China
4 shared publications - Lihe Lu
Department of Pathophysiology, Zhongshan Medical School, Sun Yat-Sen University, China (L. Lu)
4 shared publications - Qingchun Liang
Department of Anesthesiology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China
4 shared publications - Yuanzhi Ye
Department of Cardiology, Laboratory of Heart Center, Heart Center Zhujiang Hospital, Southern Medical University Guangzhou China
4 shared publications - Zirong Lan
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China. (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.)
4 shared publications
Latest Publications
- 4 September 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.
- 4 September 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.
- 27 June 2025
- Published by Wolters Kluwer Health in Circulation Research
E3 Ubiquitin Ligase TRIM16-Mediated K63-linked Ubiquitination of DAB2 Enhances Integrin β1 Endocytosis to Facilitate Vascular Calcification
BACKGROUND: Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD), and the underlying mechanisms remain elusive. Several studies have indicated an important role of protein ubiquitination in vascular calcification. However, the role of E3 ubiquitin ligases in vascular calcification remains poorly understood. METHODS: Calcification of vascular smooth muscle cells (VSMCs) was induced by high phosphate. CKD mouse model was induced by an adenine diet, and CKD rat model was established using 5/6 nephrectomy method. Adenovirus, siRNA, adeno-associated virus, and smooth muscle cell–specific TRIM16 (tripartite motif 16) knockout mice were used to investigate the role of TRIM16 in vascular calcification. Immunoprecipitation–mass spectrometry, and ubiquitination assay were used to dissect how TRIM16 regulates vascular calcification. RESULTS: Bioinformatic analysis suggested that E3 ubiquitin TRIM16 could be a key modulator of vascular calcification. TRIM16 expression was increased during vascular calcification. Overexpression of TRIM16 exacerbated VSMC calcification and aortic calcification of CKD rats. By contrast, the knockdown of TRIM16 alleviated VSMC calcification and aortic calcification in CKD rats. Moreover, the deletion of TRIM16 inhibited VSMC calcification and aortic calcification in VitD3-overloaded mice and CKD mice. Mechanistically, immunoprecipitation–mass spectrometry revealed that DAB2 (disabled homolog 2) was the potential downstream target of TRIM16. Coimmunoprecipitation showed that the SPRY domain of TRIM16 interacted with the proline-rich domain of DAB2. Moreover, ubiquitination assay revealed that the SPRY domain of TRIM16 is required for TRIM16-mediated K63-linked ubiquitination of DAB2 at K656 residue. Of note, the knockdown of DAB2 inhibited TRIM16-induced VSMC calcification. Furthermore, knockdown of DAB2 antagonized endocytosis of integrin β1 and subsequent activation of FAK (focal adhesion kinase)-STAT3 (signal transduction and transcriptional activation factor 3) signaling induced by overexpression of TRIM16. CONCLUSIONS: Our study for the first time demonstrates that E3 ubiquitin ligase TRIM16 catalyzes K63-ubiquitination of the endocytic adaptor DAB2, leading to endocytosis of integrin β1 and activation of FAK-STAT3 signaling, and subsequently exacerbates vascular calcification, suggesting that TRIM16-DAB2 axis is a promising therapeutic target for vascular calcification.
- 27 June 2025
- Published by Wolters Kluwer Health in Circulation Research
E3 Ubiquitin Ligase TRIM16-Mediated K63-linked Ubiquitination of DAB2 Enhances Integrin β1 Endocytosis to Facilitate Vascular Calcification
BACKGROUND: Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD), and the underlying mechanisms remain elusive. Several studies have indicated an important role of protein ubiquitination in vascular calcification. However, the role of E3 ubiquitin ligases in vascular calcification remains poorly understood. METHODS: Calcification of vascular smooth muscle cells (VSMCs) was induced by high phosphate. CKD mouse model was induced by an adenine diet, and CKD rat model was established using 5/6 nephrectomy method. Adenovirus, siRNA, adeno-associated virus, and smooth muscle cell–specific TRIM16 (tripartite motif 16) knockout mice were used to investigate the role of TRIM16 in vascular calcification. Immunoprecipitation–mass spectrometry, and ubiquitination assay were used to dissect how TRIM16 regulates vascular calcification. RESULTS: Bioinformatic analysis suggested that E3 ubiquitin TRIM16 could be a key modulator of vascular calcification. TRIM16 expression was increased during vascular calcification. Overexpression of TRIM16 exacerbated VSMC calcification and aortic calcification of CKD rats. By contrast, the knockdown of TRIM16 alleviated VSMC calcification and aortic calcification in CKD rats. Moreover, the deletion of TRIM16 inhibited VSMC calcification and aortic calcification in VitD3-overloaded mice and CKD mice. Mechanistically, immunoprecipitation–mass spectrometry revealed that DAB2 (disabled homolog 2) was the potential downstream target of TRIM16. Coimmunoprecipitation showed that the SPRY domain of TRIM16 interacted with the proline-rich domain of DAB2. Moreover, ubiquitination assay revealed that the SPRY domain of TRIM16 is required for TRIM16-mediated K63-linked ubiquitination of DAB2 at K656 residue. Of note, the knockdown of DAB2 inhibited TRIM16-induced VSMC calcification. Furthermore, knockdown of DAB2 antagonized endocytosis of integrin β1 and subsequent activation of FAK (focal adhesion kinase)-STAT3 (signal transduction and transcriptional activation factor 3) signaling induced by overexpression of TRIM16. CONCLUSIONS: Our study for the first time demonstrates that E3 ubiquitin ligase TRIM16 catalyzes K63-ubiquitination of the endocytic adaptor DAB2, leading to endocytosis of integrin β1 and activation of FAK-STAT3 signaling, and subsequently exacerbates vascular calcification, suggesting that TRIM16-DAB2 axis is a promising therapeutic target for vascular calcification.
- 14 March 2025
- Published by Wiley in The Journal of Pathology
- Vol. 266 (1) , 109-123
Thrombospondin‐1 binds to integrin β3 to inhibit vascular calcification through suppression of NF‐κB pathway
Vascular calcification is an important risk factor related to all‐cause mortality of cardiovascular events in patients with chronic kidney disease (CKD). Vascular extracellular matrix (ECM) proteins have been demonstrated to regulate vascular calcification. ECM protein thrombospondin 1 (THBS1/TSP‐1) plays a critical role in the regulation of vascular diseases. However, whether THBS1 is involved in vascular calcification in CKD patients remains unclear. In this study, RNA sequencing datasets from the Gene Expression Omnibus (GEO) database GSE146638 showed that THBS1 was upregulated in the aortas of CKD rats. Enzyme‐linked immunosorbent assay (elisa) revealed that serum THBS1 levels were increased in CKD patients with thoracic calcification. Western blotting and immunofluorescence analysis showed that THBS1 expression was increased in calcified vascular smooth muscle cells (VSMCs) and arteries. THBS1 knockdown exacerbated rat VSMC calcification induced by high phosphorus and calcium, as shown by Alizarin red staining and calcium content assays. Conversely, THBS1 overexpression attenuated VSMC calcification and abdominal aortic calcification in rats with CKD. Moreover, addition of recombinant THBS1 protein inhibited calcification of VSMCS and human arterial rings. Smooth muscle cell‐specific knockout of THBS1 mice treated with vitamin D3 displayed aggravated aortic calcification. Mechanistically, the protein–protein interaction database STRING (http://string-db.org/) analysis and coimmunoprecipitation assays revealed THBS1 bound to integrin β3. Reduction of integrin β3 levels abrogated the protective effect of THBS1 on vascular calcification. RNA‐seq analysis revealed that THBS1 overexpression modulated the nuclear factor‐kappa B (NF‐κB) signaling pathway. Of note, the inhibitory effect of THBS1 overexpression on the NF‐κB signal was abolished by knockdown of integrin β3. In conclusion, THBS1 interacts with integrin β3 to inhibit vascular calcification through suppression of NF‐κB signal, suggesting a promising therapeutic target for vascular calcification in CKD. © 2025 The Pathological Society of Great Britain and Ireland.
- 14 March 2025
- Published by Wiley in The Journal of Pathology
- Vol. 266 (1) , 109-123
Thrombospondin‐1 binds to integrin β3 to inhibit vascular calcification through suppression of NF‐κB pathway
Vascular calcification is an important risk factor related to all‐cause mortality of cardiovascular events in patients with chronic kidney disease (CKD). Vascular extracellular matrix (ECM) proteins have been demonstrated to regulate vascular calcification. ECM protein thrombospondin 1 (THBS1/TSP‐1) plays a critical role in the regulation of vascular diseases. However, whether THBS1 is involved in vascular calcification in CKD patients remains unclear. In this study, RNA sequencing datasets from the Gene Expression Omnibus (GEO) database GSE146638 showed that THBS1 was upregulated in the aortas of CKD rats. Enzyme‐linked immunosorbent assay (elisa) revealed that serum THBS1 levels were increased in CKD patients with thoracic calcification. Western blotting and immunofluorescence analysis showed that THBS1 expression was increased in calcified vascular smooth muscle cells (VSMCs) and arteries. THBS1 knockdown exacerbated rat VSMC calcification induced by high phosphorus and calcium, as shown by Alizarin red staining and calcium content assays. Conversely, THBS1 overexpression attenuated VSMC calcification and abdominal aortic calcification in rats with CKD. Moreover, addition of recombinant THBS1 protein inhibited calcification of VSMCS and human arterial rings. Smooth muscle cell‐specific knockout of THBS1 mice treated with vitamin D3 displayed aggravated aortic calcification. Mechanistically, the protein–protein interaction database STRING (http://string-db.org/) analysis and coimmunoprecipitation assays revealed THBS1 bound to integrin β3. Reduction of integrin β3 levels abrogated the protective effect of THBS1 on vascular calcification. RNA‐seq analysis revealed that THBS1 overexpression modulated the nuclear factor‐kappa B (NF‐κB) signaling pathway. Of note, the inhibitory effect of THBS1 overexpression on the NF‐κB signal was abolished by knockdown of integrin β3. In conclusion, THBS1 interacts with integrin β3 to inhibit vascular calcification through suppression of NF‐κB signal, suggesting a promising therapeutic target for vascular calcification in CKD. © 2025 The Pathological Society of Great Britain and Ireland.
- 6 April 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (7) , e23592
Oxidized phospholipid POVPC contributes to vascular calcification by triggering ferroptosis of vascular smooth muscle cells
Vascular calcification is an actively regulated biological process resembling bone formation, and osteogenic differentiation of vascular smooth muscle cells (VSMCs) plays a crucial role in this process. 1‐Palmitoyl‐2‐(5′‐oxo‐valeroyl)‐sn‐glycero‐3‐phosphocholine (POVPC), an oxidized phospholipid, is found in atherosclerotic plaques and has been shown to induce oxidative stress. However, the effects of POVPC on osteogenic differentiation and calcification of VSMCs have yet to be studied. In the present study, we investigated the role of POVPC in vascular calcification using in vitro and ex vivo models. POVPC increased mineralization of VSMCs and arterial rings, as shown by alizarin red staining. In addition, POVPC treatment increased expression of osteogenic markers Runx2 and BMP2, indicating that POVPC promotes osteogenic transition of VSMCs. Moreover, POVPC increased oxidative stress and impaired mitochondria function of VSMCs, as shown by increased ROS levels, impairment of mitochondrial membrane potential, and decreased ATP levels. Notably, ferroptosis triggered by POVPC was confirmed by increased levels of intracellular ROS, lipid ROS, and MDA, which were decreased by ferrostatin‐1, a ferroptosis inhibitor. Furthermore, ferrostatin‐1 attenuated POVPC‐induced calcification of VSMCs. Taken together, our study for the first time demonstrates that POVPC promotes vascular calcification via activation of VSMC ferroptosis. Reducing the levels of POVPC or inhibiting ferroptosis might provide a novel strategy to treat vascular calcification.
- 6 April 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (7) , e23592
Oxidized phospholipid POVPC contributes to vascular calcification by triggering ferroptosis of vascular smooth muscle cells
Vascular calcification is an actively regulated biological process resembling bone formation, and osteogenic differentiation of vascular smooth muscle cells (VSMCs) plays a crucial role in this process. 1‐Palmitoyl‐2‐(5′‐oxo‐valeroyl)‐sn‐glycero‐3‐phosphocholine (POVPC), an oxidized phospholipid, is found in atherosclerotic plaques and has been shown to induce oxidative stress. However, the effects of POVPC on osteogenic differentiation and calcification of VSMCs have yet to be studied. In the present study, we investigated the role of POVPC in vascular calcification using in vitro and ex vivo models. POVPC increased mineralization of VSMCs and arterial rings, as shown by alizarin red staining. In addition, POVPC treatment increased expression of osteogenic markers Runx2 and BMP2, indicating that POVPC promotes osteogenic transition of VSMCs. Moreover, POVPC increased oxidative stress and impaired mitochondria function of VSMCs, as shown by increased ROS levels, impairment of mitochondrial membrane potential, and decreased ATP levels. Notably, ferroptosis triggered by POVPC was confirmed by increased levels of intracellular ROS, lipid ROS, and MDA, which were decreased by ferrostatin‐1, a ferroptosis inhibitor. Furthermore, ferrostatin‐1 attenuated POVPC‐induced calcification of VSMCs. Taken together, our study for the first time demonstrates that POVPC promotes vascular calcification via activation of VSMC ferroptosis. Reducing the levels of POVPC or inhibiting ferroptosis might provide a novel strategy to treat vascular calcification.
- 30 April 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (11) , 7342-7355
Nkx2‐3 induces autophagy inhibiting proliferation and migration of vascular smooth muscle cells via AMPK/mTOR signaling pathway
Vascular remodeling and restenosis are common complications after percutaneous coronary intervention. Excessive proliferation and migration of vascular smooth muscle cells (VSMCs) play important roles in intimal hyperplasia‐induced vascular restenosis. NK2 Homeobox 3 (Nkx2‐3), a critical member of Nkx family, is involved in tissue differentiation and organ development. However, the role of Nkx2‐3 in VSMCs proliferation and migration remains unknown. In this study, we used carotid balloon injury model and platelet‐derived growth factor‐BB (PDGF)‐treated VSMCs as in vivo and in vitro experimental models. EdU assay and CCK‐8 assay were used to detect cell proliferation. Migration was measured by scratch test. Hematoxylin and eosin staining and immunohistochemistry staining were used to evaluate the intimal hyperplasia. The autophagy level was detected by fluorescent mRFP‐GFP‐LC3 in vitro and by transmission electron microscopy in vivo. It was shown that Nkx2‐3 was upregulated both in balloon injured carotid arteries and PDGF‐stimulated VSMCs. Adenovirus‐mediated Nkx2‐3 overexpression inhibited intimal hyperplasia after balloon injury, and suppressed VSMCs proliferation and migration induced by PDGF. Conversely, silencing of Nkx2‐3 by small interfering RNA exaggerated proliferation and migration of VSMCs. Furthermore, we found that Nkx2‐3 enhanced autophagy level, while the autophagy inhibitor 3‐MA eliminated the inhibitory effect of Nkx2‐3 on VSMCs proliferation and migration both in vivo and in vitro. Moreover, Nkx2‐3 promoted autophagy in VSMCs by activating the AMP‐activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway. These results demonstrated for the first time that Nkx2‐3 inhibited VSMCs proliferation and migration through AMPK/mTOR‐mediated autophagy.
- 30 April 2021
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (11) , 7342-7355
Nkx2‐3 induces autophagy inhibiting proliferation and migration of vascular smooth muscle cells via AMPK/mTOR signaling pathway
Vascular remodeling and restenosis are common complications after percutaneous coronary intervention. Excessive proliferation and migration of vascular smooth muscle cells (VSMCs) play important roles in intimal hyperplasia‐induced vascular restenosis. NK2 Homeobox 3 (Nkx2‐3), a critical member of Nkx family, is involved in tissue differentiation and organ development. However, the role of Nkx2‐3 in VSMCs proliferation and migration remains unknown. In this study, we used carotid balloon injury model and platelet‐derived growth factor‐BB (PDGF)‐treated VSMCs as in vivo and in vitro experimental models. EdU assay and CCK‐8 assay were used to detect cell proliferation. Migration was measured by scratch test. Hematoxylin and eosin staining and immunohistochemistry staining were used to evaluate the intimal hyperplasia. The autophagy level was detected by fluorescent mRFP‐GFP‐LC3 in vitro and by transmission electron microscopy in vivo. It was shown that Nkx2‐3 was upregulated both in balloon injured carotid arteries and PDGF‐stimulated VSMCs. Adenovirus‐mediated Nkx2‐3 overexpression inhibited intimal hyperplasia after balloon injury, and suppressed VSMCs proliferation and migration induced by PDGF. Conversely, silencing of Nkx2‐3 by small interfering RNA exaggerated proliferation and migration of VSMCs. Furthermore, we found that Nkx2‐3 enhanced autophagy level, while the autophagy inhibitor 3‐MA eliminated the inhibitory effect of Nkx2‐3 on VSMCs proliferation and migration both in vivo and in vitro. Moreover, Nkx2‐3 promoted autophagy in VSMCs by activating the AMP‐activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) signaling pathway. These results demonstrated for the first time that Nkx2‐3 inhibited VSMCs proliferation and migration through AMPK/mTOR‐mediated autophagy.